These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 38901496

  • 1. Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe: author's response.
    Lange C, Kherabi Y, Guglielmetti L, Duarte R, Günther G, Tuberculosis Network European Trials group.
    Clin Microbiol Infect; 2024 Sep; 30(9):1207-1208. PubMed ID: 38901496
    [No Abstract] [Full Text] [Related]

  • 2. Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe.
    Günther G, Guglielmetti L, Kherabi Y, Duarte R, Lange C, Tuberculosis Network European Trials group.
    Clin Microbiol Infect; 2024 Sep; 30(9):1197.e1-1197.e4. PubMed ID: 38490355
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A bedaquiline, pretomanid, moxifloxacin, and pyrazinamide regimen for drug-susceptible and drug-resistant tuberculosis.
    Deng G, Fu L.
    Lancet Infect Dis; 2024 Sep; 24(9):940-941. PubMed ID: 38768618
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis.
    Xu J, Li SY, Almeida DV, Tasneen R, Barnes-Boyle K, Converse PJ, Upton AM, Mdluli K, Fotouhi N, Nuermberger EL.
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30833432
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.
    Yang JS, Kim KJ, Choi H, Lee SH.
    Ann Lab Med; 2018 Nov; 38(6):563-568. PubMed ID: 30027700
    [Abstract] [Full Text] [Related]

  • 11. Bedaquiline or delamanid for rifampin-resistant tuberculosis?
    Lessem E, Cox V, Furin J.
    Lancet Respir Med; 2017 Oct; 5(10):772-774. PubMed ID: 28887015
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way.
    Deshpande D, Srivastava S, Nuermberger E, Pasipanodya JG, Swaminathan S, Gumbo T.
    Clin Infect Dis; 2016 Nov 01; 63(suppl 3):S95-S101. PubMed ID: 27742640
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model.
    Li SY, Converse PJ, Betoudji F, Lee J, Mdluli K, Upton A, Fotouhi N, Nuermberger EL.
    Antimicrob Agents Chemother; 2023 Apr 18; 67(4):e0003523. PubMed ID: 36920217
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.